| Outcome Measures: |
Primary: Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin, A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0., Baseline and Week 24|Number of Participants Who Experienced an Adverse Event, An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions., Up to 26 weeks|Number of Participants Who Discontinued Study Drug Due to an Adverse Event, An adverse event is any untoward medical occurrence in a participant administered study drug which does not necessarily have a causal relationship with the treatment. Adverse events may include the onset of new illness and the exacerbation of pre-existing conditions., Up to 24 weeks | Secondary: Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin, This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0., Baseline and Week 24|Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin, This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0., Baseline and Week 24|Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin, A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0., Baseline and Week 24|Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone, A1C was measured as a percent. This change from baseline reflects the A1C percent at Week 24 minus the A1C percent at Week 0., Baseline and Week 24|Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and a Sulfonylurea in Combination With Metformin, This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0., Baseline and Week 24|Change From Baseline in 2-hr PMG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone, This change from baseline reflects the 2-hr PMG level at Week 24 minus the 2-hr PMG level at Week 0., Baseline and Week 24|Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea in Combination With Metformin, This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0., Baseline and Week 24|Change From Baseline in FPG Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone, This change from baseline reflects the FPG level at Week 24 minus the FPG level at Week 0., Baseline and Week 24
|
